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doi:10.1016/j.ejvs.2009.10.014Abstract Objective: The aim of this review is to delineate the association between abdom-
inal aortic aneurysms (AAAs) and diabetes mellitus. Mechanisms for the underlying association
are then discussed.
Methods: A systematic review of the English-language literature using PubMed, EMBASE and
Cochrane databases was undertaken up to September 2009. Studies reporting appropriate
prevalence data were identified and a meta-analysis performed.
Results: Eleven studies were identified. The prevalence of diabetes mellitus in studied
patients with AAA ranged from 6% to 14%. The prevalence of diabetes in control patients
without AAA ranged from 17% to 36%. Pooled analysis suggested a reduced rate of diabetes
amongst people with AAA compared to those without (OR 0.65, 0.60e0.70, p< 0.001).
Conclusions: Studies so far suggest a protective role for diabetes on the development of AAA.
Further research is required to demarcate the underlying mechanisms for this possible
association.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Diabetes mellitus affects around 4% of the UK population.1
The prevalence of diagnosed type 2 diabetes in men over 60
e the group most at risk of developing abdominal aortic
aneurysms (AAAs) e is estimated between 10e15%.2,3 The7786 250 850; fax: þ44 0113
ac.uk (D.J.A. Scott).
ty for Vascular Surgery. Publisheprevalence of both diabetes and AAA has risen in recent
years.4e6 Abdominal aortic aneurysm (AAA) is defined as
a permanent dilatation of the abdominal aorta and is the
tenth leading cause of death in older men.7
Despite theoretical common pathogenic mechanisms,
the association between AAA and diabetes remains
unclear and published work in this area is limited,
incomplete and often conflicting. In this review, we scan
the literature aiming to further delineate the prevalence
of diabetes in people with AAA. In addition, we outline
possible factors that explain the link between diabetes
and AAA.d by Elsevier Ltd. All rights reserved.
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A literature search was performed using PubMed, Embase
and the Cochrane databases. The last search was per-
formed in September 2009. Results were limited to human
studies written in the English language in the last thirty
years. The key search words used were AAA, aneurysm,
diabetes and glycaemia. The titles and relevant abstracts
were screened for studies which included statistically
analysed prevalence data for diabetes in AAA. In addition,
the references of eligible papers were screened for further
relevant studies. Statistics were performed using Compre-
hensive Meta Analysis version 2 (HewlettePackard 2008).
Prevalence of Abdominal Aortic Aneurysm in
Diabetes
Eleven papers were identified that analysed the association
between diabetes and AAA (Table 1), of which the first
three produced conflicting results. Simoni et al.8 performed
a population-based, prospective screening program in one
district in Italy on patients aged 65e75 years. Of the 1601
patients screened, the prevalence of diabetes was 14% in
individuals with normal aortas (<2.5 cm; nZ 1504), and
14% in those with AAA (>3 cm, nZ 70; pZ 0.964).8 A
similar screening study carried out in the UK, which
compared the co-morbidities in people aged 65e80 years,
found no significant difference in the prevalence of dia-
betes in patients with or without AAA (OR 0.8, 95% CI 0.41e
1.58; pZ 0.50).9 Both of these studies had approximately
equal numbers of men and women (Table 1). Conversely,
a retrospective caseecontrol trial undertaken in two
teaching hospitals in Boston10 compared the rates of dia-
betes in patients who had aortic surgery against patients of
a similar age range who were admitted for appendicec-
tomy. They demonstrated a significantly negative associa-
tion between AAA and diabetes (OR 0.78, 0.62e0.98;
pZ 0.03).10 This study, however, included people of
a younger age group (50e84 years). In all three of these
early studies, no mention was made on the criteria used to
diagnose diabetes or concurrent medications.
A subsequent Australian study analysed the prevalence
of AAA in a group of known diabetic men over 60 years who
had no previous history of aortic disease.11 Seven of the 300
men screened were found to have AAA (2.3%). Although
they had no control group with which to compare this
figure, they reported that when measured against the
prevalence of AAA in non-diabetic populations in other
studies the result was significantly lower.11
Lederle et al.12 reported early results of the Aneurysm
Detection and Management (ADAM) study, a large ongoing
population-based screening trial which aims to compare
a conservative observation strategy with a surgical repair
approach for small aneurysms. In this study 73,451 subjects
aged 50e79 with no previous history of AAA were screened
of whom 97% were males. A negative association was
demonstrated between diabetes and AAA measuring
between: (i) 3.0e3.9 cm (OR 0.68, 95% CI 0.60e0.77); and
(ii) 4 cm (OR 0.54, 0.44e0.65).12 The authors claimed that
this negative association was unexpected as atherosclerosis
traditionally shares many risk factors with AAA. The samegroup published further results using 52,745 new subjects
recruited to the same trial three years later.13 These results
confirmed the negative relationship between diabetes and
AAA in small (3.0e3.9 cm) aneurysms (OR 0.60, 0.50e0.71)
and larger (>4 cm) aneurysms (OR 0.50, 0.39e0.65).13
Neither of these two reports investigated the association
between diabetes and large aneurysms (>5.5 cm). It is
possible that diabetes is only protective at early stages of
AAA and that after a certain size mechanical factors play
a greater role in aneurysm expansion. Similarly to earlier
studies, the criteria used for the diagnosis of diabetes were
unclear.
Since the publication of the ADAM data, three more
studies demonstrated similar results. Blanchard et al.14
compared the rates of diabetes in patients with newly
diagnosed AAA with control subjects who underwent
ultrasound examination for similar indications, but were
not found to have aneurysmal disease (12% vs. 17%, OR
0.32, 0.12e0.88). A sub-analysis compared the rates of
diabetes in aneurysms <4 cm (OR 0.50, 0.17e1.46) and
aneurysms 4 cm (OR 0.15, 0.03e0.79) with rates in non-
aneurysmal subjects.14 This study had a clear advantage by
explicitly defining diabetes as a fasting blood glucose above
7 mmol/l or a physician’s diagnosis with concurrent hypo-
glycaemic or insulin use.
Kang et al.15 examined the role of routine ultrasound
screening for patients with carotid artery stenosis for AAA,
as some studies have found that patients with carotid
stenosis have a higher prevalence of AAA compared with
the general population.16 In patients with >50% carotid
stenosis, the prevalence of AAA 3.0 cm was 21.9% in non-
diabetics vs. 9.2% in diabetics (OR 0.58; pZ 0.002), and the
prevalence of AAA 4.0 cm was 10.2% in non-diabetics vs.
2.8% in diabetics (OR 0.32; pZ 0.002). The authors found
a significant negative association between the development
of AAA and diabetes within this subset. They concluded that
non-diabetic patients with carotid stenosis should be
screened for AAA disease.15 This study provided no criteria
for the diagnosis of diabetes.
In order to look more closely at the differences in risk
factors between AAA and aorto-iliac occlusive disease,
Shteinberg et al.17 conducted a prospective study
comparing patients undergoing AAA surgery and those
having operative intervention for aorto-occlusive disease
(AOD). They reported a 6% prevalence of diabetes in AAA
and a 36% prevalence in AOD (p< 0.001).17 In this hospital-
based population, the patients with AOD would represent
a group with more advanced disease of which diabetes
would be a significant factor. The reported difference is
therefore likely to represent an overestimation.
The Health in Men study, a large, population-based study
conducted in Western Australia, assessed the relationship
between diabetes and AAA in men over the age of 65.18,19
They reported that diabetes was a negative risk factor for
AAA development (ORZ 0.79, 95% CI 0.63e0.98), with
a diminishing risk with increasing duration of diabetes: 3e5
years (OR 0.50, 0.27e0.89), 6e12 years (OR 0.57, 0.33e
0.97), over 12 years (OR 0.37, 0.19e0.70).19
A recent analysis by Lederle et al. looked at AAA events
in a cohort of 161,808 post-menopausal women followed-up
for a mean of 7.8 years.20 The study found that women who
suffered an AAA event had a lower prevalence of diabetes
202 S. Shantikumar et al.(ORZ 0.29, 0.13e0.68). The authors concluded that the
negative association between diabetes and AAA seen in
men is also evident in women.20
In summary, nine studies found a lower prevalence of
AAA in individuals with diabetes,10e15,7e19 whereas 2
studies found no difference.8,9 Of the studies reportingTable 1 Summary of studies reporting prevalence rates of diab
Author Study type Subje
Simoni et al., 19958
Population-based
screening study
(over 3 years)
Italy
nZ 16
46% m
Age 65
DM no
Kanagasabay et al., 19969
Population-based
screening study
(over 2 years)
London
nZ 53
43% m
Age 65
DM no
LaMorte et al., 199510
Caseecontrol study
(from 4 years)
Boston
(1) Pa
AAA (n
(2) Ap
admis
71% m
Age 50
DM no
Mattes et al., 199711
Population-based
screening study
Australia
Diabet
nZ 30
Over 6
DM no
Lederle et al., 199712
Population-based
screening study
Boston
nZ 73
97% m
Age 50
DM no
Lederle et al., 200013
Population-based
screening study
(over 3 years)
Boston
nZ 52
97% m
Age 50
DM no
Blanchard et al., 200014
Caseecontrol study
Canada
(1) Ne
AAA (n
(2) Co
DM de
glucos
insulindiabetes as a negative risk factor for AAA development,
three included data from the Aneurysm Detection and
Management trial.12,13,15
We performed a meta-analysis of the above studies
(Fig. 1). Of the eleven data sets, four were excluded
because there was no control group,11 there was a pooretes in abdominal aortic aneurysms.
cts Results
01
ale
e75 years
t defined
14.1% of patients normal aortas
(<2.5 cm, nZ 1504)) had DM
14.1% of patients with AAA
(>3.0 cm, nZ 70) had DM
No significant difference (pZ 0.964)
(Note 27 patients had aortas
between 2.5 and 3.0 cm)
92
ale
e80 years
t defined
218 people had AAA
No significant difference in diabetes
prevalence
(OR 0.8, 95% CI 0.41e1.58; pZ 0.50)
tients with
Z 4682)
pendicectomy
sions (nZ 3188)
ale
e84
t defined
Significantly lower rate of DM in AAA
compared to appendicectomy
(OR 0.78, 95% CI 0.62e0.98; pZ 0.03)
ic men
0
0 years
t defined
7 of 300 diabetic men screened had
AAA (2.3%)
No control group with which to calculate
significance
,451
ale
e79
t defined
12% of those with AAA (nZ 3366) had DM
19% of those without AAA had DM
Significantly lower rate of DM in AAA
compared to no-AAA
OR 0.68 (95% CI 0.60e0.77) for small
AAA (3.0e3.9 cm)
OR 0.54 (95% CI 0.44e0.65) for larger
AAA (>4.0 cm)
,745
ale
e79
t defined
1917 had AAA
Significantly lower rate of DM in AAA
compared to no-AAA
OR 0.60 (95% CI 0.50e0.71) for small
AAA (3.0e3.9 cm)
OR 0.50 (95% CI 0.39e0.65) for larger
AAA (>4.0 cm)
wly diagnosed
Z 98)
ntrols (nZ 102)
fined as fasting
e >7 or use of
/hypoglycaemics
12% of those with AAA had DM
17% of those without AAA had DM
(OR 0.32, 95% CI 0.12e0.88)
Table 1 (continued )
Author Study type Subjects Results
Kang et al., 199915
Population-based
screening study
Boston
(1) >50% carotid
stenosis (nZ 374)
(2) <50% carotid
stenosis (nZ 139)
(3) ADAM study
(nZ 2477)
Relative risk of AAA is 2e3 times more in
carotid stenosis rather than in the general
screened population (18% group 1 vs. 7%)
Prevalence AAA 3 cm in carotid stenosis
22% no-DM vs. 9% DM
(OR 0.58; pZ 0.002)
Prevalence AAA 4 cm in carotid stenosis
10% no-DM vs. 3% DM
(OR 0.32; pZ 0.002)
Thus only patients who are not
diabetic account for increased prevalence
Shteinberg et al., 200017
Prospective study
(over 4 years)
Israel
(1) Patients with
AAA (nZ 82)
(2) Patients with
AOD (nZ 73)
Decreased prevalence of DM in AAA vs. AOD
(6% vs. 36%, p< 0.001)
Jamrozik et al., 2000
18
Le et al., 2007
19
Population-based
screening study
(over 3 years)
Australia
nZ 12,203
Age 65e83
Men only
Significantly lower rate of DM in
AAA compared to no-AAA
(ORZ 0.79, 95% CI 0.63e0.98)
Inverse correlation between fasting
glucose and aortic diameter in
non-diabetic men (correlation
coefficient e 0.0024, pZ 0.0027)
Lederle et al., 200820
Prospective observational
cohort study (over 7.8 years)
NZ 161,808
Post-menopausal
women
Decreased rate of diabetes in women
who had AAA events
(ORZ 0.29, 95% CI 0.13e0.68)
Figure 1 Pooled analysis of the studies reporting prevalence
rates of diabetes amongst patients with AAA. Note the studies
by Lederle et al. reported separate odds ratios in patients with
aneurysms between 3 and 4 cm (denoted by the suffix ‘a’) and
those with aneurysms above 4 cm (denoted by suffix ‘b’).
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because they only looked at a particular subgroup (patients
with carotid stenosis15 or women suffering AAA-related
events20). Pooled analysis of the remaining seven papers
demonstrated reduced odds of diabetes in patients with
AAA (ORZ 0.65, 0.60e0.70, p< 0.001).8e10,12e14,18 If
analysis was restricted to the five population-based
screening studies, pooled analysis still showed a reduced
odds of diabetes in AAA (ORZ 0.64, 0.59e0.69,
p< 0.001).8,9,12,13,18 The two studies reported by Lederle
et al. provided results from a multivariate analysis and
separated results according to size of aneurysm (3e4 cm vs.
4 cm).12,13 When these were removed from the analysis,
the remaining three studies still suggested a reduced
prevalence of diabetes in patients with AAA (ORZ 0.81,
0.66e0.99, pZ 0.038).8,9,18
Potential Mechanisms for the Protective Effect
of Diabetes
The predominant risk factors for AAA aremale sex, increasing
age, smoking, hyperlipidaemia, hypertension and a family
history.12,21 Because atherosclerosis shares similar risk
factors it has traditionally been thought of as the underlying
pathogenesis in AAA.22 The evidence above portraying
a decreased prevalence of AAA in diabetics suggests that
atherosclerosis is an associated feature, rather than
204 S. Shantikumar et al.a causative factor, of aneurysmal disease. The biological
processes underlying this relationship are as yet undeter-
mined, but can be distinguished as changes in the aortic wall
and characteristics of the mural thrombus within it.
Biology of the wall
Research in vitro and in vivo has described potential
mechanisms involving the aortic wall that result in aneu-
rysmal disease. This has been the subject of a recent
review by Norman et al.,23 and we present an updated
summary. The walls of AAA show evidence of increased
proteolytic activity with resulting collagen and elastin
depletion.24 Matrix metalloproteinases (MMPs) are a group
of proteolytic enzymes which exhibit an increased activity
in human aneurysmal tissue.25 Of these, smooth muscle cell
MMP-2 and macrophage-derived MMP-9 have been shown to
be principally involved in the breakdown of matrix proteins,
including elastin, and degradation of the vessel wall in
aneurysmal disease. Elevated concentrations of both MMP-2
and MMP-9 have been found in patients with AAA,26,27 and
mice deficient in either MMP-2 or MMP-9 fail to develop
aortic dilatation compared to wild-type mice.28 Whilst little
is known about the factors that initiate the biological
process of matrix destruction, there are a number of
mechanistic possibilities.29
This review suggests that individuals with diabetes
exhibit a lower prevalence of AAA.13 Furthermore, studies
have found the expansion rate of small AAA to be slower in
diabetes compared with non-diabetic subjects.30,31 Dia-
betes is characterised by an increased synthesis and
reduced degradation of the matrix, resulting in enhanced
matrix volume.23 In vitro studies have demonstrated that
hyperglycaemia results in increased collagen synthesis.32Figure 2 The potential influences of diabetes onFurthermore, abdominal aorta thickness has been found to
be greater in people with diabetes.33 A human study found
that MMP-2 and MMP-9 concentrations were reduced in the
coronary arteries of diabetic patients.34 A similar reduction
in the activity of MMPs in the aorta of diabetic patients may
decelerate the matrix loss necessary for the pathogenesis
of AAA.
The high ambient glucose concentrations in diabetes
result in glycation of the extracellular matrix (ECM), with
a subsequently elevated formation of advanced glycation
end products (AGEs).30 AGEs form covalent cross-links
between proteins, including elastin and collagen in the
vessel wall,35 and promote smooth muscle cell prolifera-
tion.36 This may result in a stiffened wall which is resistant
to proteolysis.23 In contrast, earlier study suggested that
the stimulation of AGE receptors resulted in upregulation of
inflammatory cytokines and MMPs, contributing to aneu-
rysmal formation.37,38 In support of this, a recent study
found that serum concentrations of the AGE carbox-
ymethyllysine were lower in patients with AAA.39 Glycation
of the aortic media inhibits MMP secretion (in contrast to
glycation of atherosclerotic intima which stimulates MMP
secretion23,30).
In our own recent study, clear morphological diversity
was observed between vascular SMC cultured from patients
with and without type 2 diabetes that persisted in vitro.40
Vinculin is a focal adhesion protein that couples the
extracellular matrix to the actin cytoskeleton. Importantly,
we noted increased vinculin-positive focal adhesions and
disparate a-actin organisation in SMC from patients with
type 2 diabetes mellitus, observations that may explain the
generalised increased tissue stiffness reported in these
subjects.41 Such observations provide evidence of ‘meta-
bolic memory’,42 the long-term molecular and cellularpathogenesis of abdominal aortic aneurysms.
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is therefore possible to speculate that the metabolic milieu
of diabetes may impart a degree of resistance to aneu-
rysmal disease by creating a stiffened aortic wall less prone
to degeneration.
Additional explanation may be related to the medical
treatment of individuals with diabetes. Angiotensin-con-
verting enzyme (ACE) inhibitors, aside from their effects on
blood pressure, reduce vascular inflammation, increase
elastin deposition and inhibit MMPs.43 ACE inhibitors
prevent aortic expansion and rupture in animal models,44
and a population-based caseecontrol study found that use
of ACE inhibitors had a protective effect on AAA rupture.45
Simvastatin use has been shown to decrease MMP expres-
sion in the human AAA wall.46 Metformin decreases MMP-2
and smooth muscle cell proliferation in human aortic cells
in vitro.47 Rosiglitazone has been shown to reduce the
development and rupture of aortic aneurysms in a murine
model48 and decrease expression of MMP-9 in patients with
diabetes.49 Because of the association of hypertension,
atherosclerosis and renal impairment, diabetics are
increasingly likely to be taking ACE inhibitors, statins and
hypoglycaemic agents. The use of such medication may
contribute to the apparent protective effect of diabetes in
aneurysmal disease seen in the above studies.50 None of the
studies reported have explicitly commented on the drug
histories of recruited subjects.Biology of the clot
The fibrinolytic system may play a role in the pathogenesis
of AAA. Abdominal aortic aneurysms are associated with an
intraluminal thrombus (ILT)51 and the rate of expansion of
large AAA correlates with ILT growth.52 ILT is reported to
contain high concentrations of MMP-953,54 and signs of col-
lagenolytic activity.55 Consequently, aneurysmal wall
covered by ILT is thinner, has fewer smooth muscle cells
and is less resistant to stress.56,57 A recent study found that
the fibrin clot in type 2 diabetics is altered; being denser,
less porous and more resistant to fibrinolysis.58 On one
hand, one may subsequently expect increased ILT-mediated
expansion and rupture of larger AAA in diabetic patients.
However, the renewal of intraluminal thrombus by fibrino-
lysis releases components that are implicated in aneu-
rysmal expansion, such as MMP-9,59,60 so the more
degradation-resistant clot in diabetes may slow the rate of
expansion caused by such mediators.
Plasminogen activator inhibitor-1 (PAI-1) inhibits the
conversion of plasminogen to plasmin, thus suppresses
fibrinolysis and reduces renewal of the intraluminal
thrombus. Plasmin in turn converts pro-MMP to the active
form.61 PAI-1 therefore decreases MMP production. PAI-1 has
been shown to prevent formation of aneurysms in animal
studies.62 Furthermore, individuals with the PAI-1 5G5G
genotype, who have decreased circulating levels of PAI-1s,
are at risk of developing rapidly expanding AAA.63 Elevated
levels of PAI-1 have been reported in diabetes secondary to
insulinaemia, and this could aid aneurysmalwall stabilisation
and reduce clot degredation and renewal.64
Fig. 2 summarises the potential influences of diabetes on
abdominal aneurysm pathogenesis.Conclusions
Diabetes is known to predispose to cardiovascular disease
and therefore the negative association with abdominal
aortic aneurysms, documented by a number of studies, is
seemingly paradoxical. The aim of this review was to
analyse the link between AAA and diabetes from the
evidence published thus far. Early population and casee
control studies appear to demonstrate an overall protective
role for diabetes against the development of AAA, although
further work into prevalence associations and biological
mechanisms is clearly required, with specific attention to
the type and duration of diabetes, as well as hypoglycaemic
management and concurrent medications.
Whilst the evidence that diabetes has an inverse relation-
ship with aortic diameter may not aid the immediate
management of AAA, it may help to identify high-risk groups
for screening. Additionally, this observation may help
demonstrate the differing cellular mechanisms behind aneu-
rysmal and atherosclerotic disease, and in turn rationalise the
search for pharmacological interventions of small AAA.
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